A Study to Evaluate TVB-2640 and Trastuzumab Plus Paclitaxel or Endocrine Therapy for Treating Patients with HER2 Positive Advanced Breast Cancer

Overview

About this study

This phase II trial studies how well FASN inhibitor TVB-2640 and trastuzumab plus either paclitaxel or endocrine therapy with an aromatase inhibitor work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and trastuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Endcocrine therapy helps reduce the hormones that feed tumor cells. Giving FASN inhibitor TVB-2640 and trastuzumab with either paclitaxel or endocrine therapy may work better in treating patients with HER2 positive breast cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Pre-Registration:

  • Age ≥ 18 years.
  • Measurable disease as defined by RECIST criteria that is:
    • A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as ≥ 1.0 cm with CT scan;
    • CT component of a PET/CT; or
    • MRI and/or A malignant lymph node is considered measurable if its short axis is > 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).
    • Note: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible.
  • Received  ≤ four (4) prior chemotherapy regimens in the metastatic setting.
  • Cohort A One of the following must be true:
    • Distant disease progression during administration of combination therapy with taxane based chemotherapy and anti-HER2 therapy (trastuzumab or pertuzumab) for metastatic disease.
      • Note: patients who began treatment with this combination and discontinued taxane-based chemotherapy due to intolerability before distant disease progression are eligible;
    • Distant disease progression during administration or within 180 days of discontinuing combination therapy with taxane based chemotherapy and anti-HER2 therapy (trastuzumab or pertuzumab) in the adjuvant disease.
      • Note: Patients who began treatment with this combination and discontinued taxane-based chemotherapy due to intolerability before distant disease progression are eligible. For patients who received taxane based chemotherapy and antiHER2 therapy (trastuzumab or pertuzumab) in the neo-adjuvant setting and underwent surgical resection of primary breast disease: Distant disease progression during or within 180 days of discontinuing anti-HER2 therapy (trastuzumab or pertuzumab) in the adjuvant setting.
  • Cohort B (one of the following must be true):
    • Distant disease progression during administration of combination therapy with endocrine therapy and anti-HER2 therapy (trastuzumab or pertuzumab) for metastatic disease. Permissible endocrine therapies include an aromatase inhibitor or fulvestrant.
      • NOTE: Tamoxifen is not permissible.
    • Distant disease progression during administration of combination therapy with endocrine therapy and anti-HER2 therapy (trastuzumab or pertuzumab) in the adjuvant setting. Permissible endocrine therapies include an aromatase inhibitor or fulvestrant.
      • NOTE: Tamoxifen is not permissible.
  • Willingness to provide mandatory tumor tissue specimens for correlative research.
    • NOTE: If insufficient or no tissue is obtained by the pre-registration biopsy, an archival tissue specimen (preferably from a metastatic site) from procedure performed ≤ 2 years prior to pre-registration must be available to submit for Central Laboratory review prior to registration.
    • Exception: If there is no medically safe site for biopsy, Study Chair (Dr Haddad) may waive this requirement.

Exclusion Criteria - Pre-Registration:

Cardiac Exclusion Criteria

  • Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity/
  • Patients with a history of LVEF decline to below 50% during or after prior trastuzumab or other HER2 directed therapy ≤ 6 months prior to preregistration.
  • Patients with any class of New York Heart Association (NYHA) CHF or heart failure with preserved ejection fraction (HFPEF).
  • Patients with a history of known coronary artery disease or a myocardial infarction within 12 months prior to pre-registration.
  • Patients with persistently uncontrolled hypertension (systolic BP > 160 mm Hg or diastolic BP > 100 mm Hg) despite optimal medical therapy.
  • Patients with known unstable angina pectoris.
  • Patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia).
  • Patients with a prolonged QTc interval (≥ 450 ms).
  • Leptomeningeal disease or uncontrolled brain metastasis.
    • NOTE: Metastases treated by surgery and/or radiotherapy such that patient is neurologically stable and off steroids ≥ 4 weeks prior to preregistration are eligible.
  • Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment.
    • EXCEPTION: Grade 1 peripheral (sensory) neuropathy that has been stable for at least 3 months since completion of prior treatment.
  • Tumors involving spinal cord or heart.
  • Visceral crisis or lymphangitic spread.
    • NOTE: Visceral crisis is not the mere presence of visceral metastases, but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease.
  • Uncontrolled intercurrent non-cardiac illness including, but not limited to:
    • ongoing or active infection;
    • psychiatric illness/social situations;
    • dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy;
    • or any other conditions that would limit compliance with study requirements.
  • Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy.
    • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.
  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm.
  • History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias.
  • Prior history of hypersensitivity, drug or radiation-induced, or other immunemediated pneumonitis.
  • Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption (e.g. active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
    • Note: Concomitant therapy with proton pump inhibitors and/or H2- receptor antagonists is permissible.
  • Patient has a history of clinically significant dry eye (xerophthalmia) or other corneal abnormality, or if a contact lens wearer, does not agree to abstain from contact lens use from baseline through the last TVB-2640 dose.
  • Patients with a history of intolerance to trastuzumab (i.e., a grade 3 or 4 infusion reaction) are excluded.
    • Note: Patients with a history of mild infusion reaction to trastuzumab who have previously been successfully re-challenged after an infusion reaction with or without prophylactic medication are allowed.
  • Other invasive malignancy ≤ 3 years prior to pre-registration.
    • EXCEPTIONS: Non-melanoma skin cancer, papillary thyroid cancer, or carcinoma-in-situ of the cervix which has been adequately treated.
    • NOTE: If there is a history of prior malignancy, patients must not be receiving other antineoplastic treatment for their cancer and the disease must be inactive/stable.

Inclusion Criteria - Registration:

  • Registration must be completed ≤ 28 days of pre-registration.
  • ECOG Performance Status (PS) 0 or 1.
  • Disease characteristics.
  • Histological confirmation of HER2-positive advanced breast cancer. HER2+ is defined by 2013 ASCO/CAP guidelines.
  • For Cohort B only: Histologic confirmation of ERα positive disease (≥ 1% expression).
  • The following laboratory values obtained ≤ 14 days prior to registration:
    • Hemoglobin ≥ 9.0 g/dL;
    • Absolute neutrophil count (ANC) ≥ 1500/mm^3; Platelet count
    • ≥ 100,000/mm^3;
    • Direct bilirubin ≤ 1.5 x ULN;
    • Aspartate transaminase (AST) ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement);
    • Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula below:
  • Cockcroft-Gault Equation:
  • Creatinine clearance for males = (140 - age)(weight in kg) (72)(serum creatinine in mg/dL).
  • Creatinine clearance for females = (140 - age)(weight in kg)(0.85) (72)(serum creatinine in mg/dL).
  • Cardiac ejection fraction (LVEF) ≥ 50% by echocardiogram ≤ 28 days prior to registration.
  • Provide written informed consent.
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
  • Negative urine pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
    • NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Patient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of TVB-2640, as follows:
    • For women: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile or postmenopausal;
    • For men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile. Men whose sexual partners are of child-bearing potential must agree to use 2 methods of contraception prior to study entry, during the study, and for 3 months after the treatment period.
  • Willingness to provide mandatory tumor tissue and/or blood specimens for correlative research.

Exclusion Criteria - Registration:

  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:
    • Pregnant women;
    • Nursing women;
    • Men or women of childbearing potential who are unwilling to employ adequate contraception.
  • Any of the following therapies prior to registration:
    • Chemotherapy ≤ 3 weeks;
    • Immunotherapy ≤ 3 weeks;
    • Biologic therapy ≤3 weeks;
    • Monoclonal antibodies ≤ 3 weeks;
    • Radiation therapy ≤ 2 weeks;
    • CDK 4/6 inhibitors ≤ 4 weeks;
    • mTOR inhibitors ≤ 4 weeks.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Tufia Haddad, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Brenda Ernst, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Alvaro Moreno Aspitia, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available
.
CLS-20366138

Mayo Clinic Footer